2022
Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates
Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates. Prostate International 2022, 11: 107-112. PMID: 37409090, PMCID: PMC10318318, DOI: 10.1016/j.prnil.2022.12.005.Peer-Reviewed Original ResearchStandard pelvic lymph node dissectionPelvic lymph node dissectionLymph node dissectionNode-positive patientsNode dissectionAdjuvant treatmentRecurrence rateGleason scoreSubgroup analysisNational Comprehensive Cancer Network guidelinesPSA progression-free survivalAdjuvant androgen deprivation therapyPSA recurrence rateAndrogen deprivation therapyNode-positive diseaseProgression-free survivalGleason score 8Kaplan-Meier analysisAdditional therapeutic benefitBiochemical recurrence ratePositive prostate cancerGleason score 6Time of prostatectomyDeprivation therapyMedian follow
2020
The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithm
2016
Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications
Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications. 2016, 481-489. DOI: 10.1016/b978-0-12-800077-9.00052-9.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate cancerIntermittent androgen deprivation therapyMetastatic prostate cancer treatmentAndrogen-dependent natureProstate cancer treatmentQuality of lifeCost of treatmentDeprivation therapyAdjuvant treatmentMetastatic diseaseADT useAppropriate patientsMetabolic abnormalitiesPalliative optionSignificant complicationsRadical prostatectomyPotential complicationsBone densitySide effectsTreatment settingsOrgan systemsComplicationsOptimal timingCancer treatment
2014
Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy
Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urology 2014, 14: 30. PMID: 24708639, PMCID: PMC4005471, DOI: 10.1186/1471-2490-14-30.Peer-Reviewed Original ResearchConceptsAdjuvant radiotherapyRadical prostatectomyAmerican Urological AssociationSalvage radiotherapyASTRO guidelineBiochemical progression-free survivalLocal recurrence-free survivalCox proportional hazards analysisNeoadjuvant hormonal therapyPre-operative PSAUndetectable PSA levelsProgression-free survivalPositive surgical marginsProportional hazards analysisRecurrence-free survivalMultivariate Cox analysisRadiation Oncology guidelinesSeminal vesicle invasionOutcomes of observationPathologic GSPT2-3Adjuvant treatmentHormonal therapyFree survivalPSA levels